Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer's disease. - Wikidata - thesis-toulmin - TriplyDB

Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer's disease.

Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer's disease.

http://www.wikidata.org/entity/Q44363046

about

Erythropoietin and diabetes mellitus Erythropoietin ameliorates diabetes-associated cognitive dysfunction in vitro and in vivo WISP1: Clinical insights for a proliferative and restorative member of the CCN family Brain Uptake of Neurotherapeutics after Intranasal versus Intraperitoneal Delivery in Mice.Regeneration in the nervous system with erythropoietin Charting a course for erythropoietin in traumatic brain injury.Epobis is a Nonerythropoietic and Neuroprotective Agonist of the Erythropoietin Receptor with Anti-Inflammatory and Memory Enhancing Effects.Erythropoietin as a new therapeutic opportunity in brain inflammation and neurodegenerative diseases.Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer's and Parkinson's disease.Intranasal gene delivery for treating Parkinson's disease: overcoming the blood-brain barrier.EPO induces changes in synaptic transmission and plasticity in the dentate gyrus of rats.Warming Up to New Possibilities with the Capsaicin Receptor TRPV1: mTOR, AMPK, and Erythropoietin.Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor.In vivo and ex vivo analyses of amyloid toxicity in the Tc1 mouse model of Down syndrome.Erythropoietin Promotes Neural Plasticity and Spatial Memory Recovery in Fimbria-Fornix-Lesioned Rats.An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer's Disease.Neuroprotective effect of a new variant of Epo nonhematopoietic against oxidative stress.FoxO proteins in the nervous system.

P2860

Q26777878-E8B637B5-2ECD-4E2D-B8C1-0FB4049A1311 Q33765808-3304BBB6-1FF5-46B4-B440-B6E549B0E924 Q34381111-40F846D3-FD45-417F-875A-2D842CAA3F3C Q36052412-A626A51C-6E58-4939-86CF-C431761D47C5 Q36247651-26E964BA-A089-454A-9F1E-26C844782B69 Q36791150-D0BB131F-BD0F-472A-982B-1710EB4186EB Q37471491-B526679C-1ECC-42BF-9EB0-02BA55F015B3 Q38269081-44099113-D7CA-40D0-98CB-AC4E561CFB56 Q38303586-A42749AA-481E-439B-B1F9-9120B25C7622 Q38569775-2F1DDDAF-D5CE-4561-B033-6045A2326F4A Q40010664-9E5DF154-6CF0-4876-9D58-C42CCB7AF52F Q41082884-7A258D7C-951C-4E9E-95AB-CFC8F5AE64C7 Q44689674-0A1F5DF3-C2EC-4105-AF72-EA5DAC7A1D19 Q47319838-FED9B4CC-2642-4D22-9165-D343EFCE58F7 Q48244660-1D9D1580-CFAC-4533-831C-CF3A05096DFD Q48497465-C1D6ACBA-4503-4070-8213-D490E6889A56 Q49505001-FCBD04DA-D4B1-4E55-97FD-9623E762DD93 Q53622309-5D239563-DE60-4725-93B8-6C3B02F7EE49

P2860

Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer's disease.

http://www.wikidata.org/entity/Q44363046

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Intranasal formulation of eryt ...... model of Alzheimer's disease.

@en

Intranasal formulation of erythropoietin

@nl

type

label

Intranasal formulation of eryt ...... model of Alzheimer's disease.

@en

Intranasal formulation of erythropoietin

@nl

prefLabel

Intranasal formulation of eryt ...... model of Alzheimer's disease.

@en

Intranasal formulation of erythropoietin

@nl

P1433

Q44363046-AB7B0C7A-C0A9-42CC-9B6C-C4F5C3E38DDA

P1476

Q44363046-D185A7E8-70E6-4BD3-A7BF-F30250D6790A

P2093

Q44363046-2C40F5E2-C6CF-4F3F-B371-A827B6D143BC

Q44363046-4BD4F648-E956-4001-B93F-F434F6AC33D4

Q44363046-51BE92BC-4E2D-4925-ACC8-7A97A7D0B72A

Q44363046-7BF2AB2A-6665-4447-91B4-EFAF13B484EA

Q44363046-8A518347-E399-490C-B4B8-A5F7108DD2FF

Q44363046-911BFBBC-A8A1-4700-BB41-6CFE28222F35

Q44363046-D5268F92-DF68-4ED9-8C45-D9C24FFE7F8E

Q44363046-FDA95FA0-8B2C-4342-804E-42E78E38E9C8

P2860

Q44363046-04C7E3C1-3504-4D39-AF81-46E58BF976F2

Q44363046-0555ADAE-34F1-4DB6-A5BE-1D6F43755474

Q44363046-123DB794-79BE-4E8C-9B49-60B08D59AF5D

Q44363046-12654512-E402-4EC7-B390-AE4DB9A26397

Q44363046-145B30F9-7E82-4C89-B3C0-0A26304B3913

Q44363046-19A82E87-1B04-48B4-84CB-4A89F2C44212

Q44363046-1DCACA03-2126-4B40-8953-8C4EFFC0F184

Q44363046-1EE9F0FD-24DE-445A-9ACB-C06CA8C45DA6

Q44363046-1F19BBCA-67E4-4178-BD57-4224BF0E0FFB

Q44363046-1F240167-5564-490E-9067-D00276BE4F57

P304

Q44363046-EFE0360A-EF85-45D8-86CF-1D1B114BECB5

P31

Q44363046-C374AE15-A5F1-4894-B702-D105788D7E5E

P356

Q44363046-D3434766-D074-4FF9-9CC7-589C8B1FDA8B

P407

Q44363046-FB72EC9A-68F8-4D8A-993D-7141F74AC532

P433

Q44363046-CDB6EA77-CA25-4909-8EB0-028F77B90EA2

P478

Q44363046-C0539467-8C46-441E-A7DA-453BE6A090CB

P577

Q44363046-8AB14700-55C2-4A16-B791-95791703FEF2

P5875

Q44363046-2356212F-8547-48B3-895F-5D85EA7888F2

P698

Q44363046-E139BCA3-71F6-4DEF-A6EA-ACA17EB064D4

P921

Q44363046-0FF26739-A1FD-4311-BD4A-7D5DE8CD0637

Q44363046-E404B5D9-50DA-49F7-8F53-978A0BC075A1

P356

0269881113494939

P1433

Journal of Psychopharmacology

P1476

Intranasal formulation of eryt ...... model of Alzheimer's disease.

@en

P2093

Catherine Desrumaux

http://www.w3.org/2001/XMLSchema#string

Emeline Keller

http://www.w3.org/2001/XMLSchema#string

Gaëlle Naert

http://www.w3.org/2001/XMLSchema#string

Julío César Garcia Rodríguez

http://www.w3.org/2001/XMLSchema#string

María de la C García-Barceló

http://www.w3.org/2001/XMLSchema#string

Muhammad-Hariri Mustafa

http://www.w3.org/2001/XMLSchema#string

Tangui Maurice

http://www.w3.org/2001/XMLSchema#string

Yamila Rodríguez Cruz

http://www.w3.org/2001/XMLSchema#string

P2860

Erythropoietin enhances hippocampal long-term potentiation and memory

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury

Pathways towards and away from Alzheimer's disease

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease

Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons

AKT1 drives endothelial cell membrane asymmetry and microglial activation through Bcl-xL and caspase 1, 3, and 9

A beta oligomers - a decade of discovery

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

P304

1044-1057

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0269881113494939

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

243969952

http://www.w3.org/2001/XMLSchema#string

P698

23813967

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease